Report cover image

BioMark Diagnostics Inc (BUX) - Product Pipeline Analysis, 2026 Update

Publisher GlobalData
Published Apr 20, 2026
Length 55 Pages
SKU # GBDT21121730

Description

Summary
BioMark Diagnostics Inc (BioMark) is a developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company leverages liquid biopsy technologies to improve cancer diagnostics. It offers SSAT1 liquid biopsy assay for the active detection of enzymes with elevated levels of cancers and liquid biopsy metabolic panel assays for early diagnosis of lung cancer. BioMark's products are for the treatment of glioblastoma (GBM) cancers, breast cancer, head and neck cancer and prostate cancer. The company's products are used by oncologists and physicians for early-stage cancer detection and management. BioMark Diagnostics is headquartered in Richmond, British Columbia, Canada.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company BioMark Diagnostics Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company

Table of Contents

55 Pages
BioMark Diagnostics Inc Company Overview
BioMark Diagnostics Inc Company Snapshot
BioMark Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
BioMark Diagnostics Inc – Pipeline Analysis Overview
BioMark Diagnostics Inc - Key Facts
BioMark Diagnostics Inc - Major Products and Services
BioMark Diagnostics Inc Pipeline Products by Development Stage
BioMark Diagnostics Inc Ongoing Clinical Trials by Trial Status
BioMark Diagnostics Inc Pipeline Products Overview
Biomarker Assay - Ovarian Cancer
Biomarker Assay - Ovarian Cancer Product Overview
Detection Test - COVID-19
Detection Test - COVID-19 Product Overview
Liquid Biopsy Metabolic Panel Assay - Breast Cancer
Liquid Biopsy Metabolic Panel Assay - Breast Cancer Product Overview
Liquid Biopsy Metabolic Panel Assay - Glioblastoma
Liquid Biopsy Metabolic Panel Assay - Glioblastoma Product Overview
Liquid Biopsy Metabolic Panel Assay - Head And Neck Cancer
Liquid Biopsy Metabolic Panel Assay - Head And Neck Cancer Product Overview
Liquid Biopsy Metabolic Panel Assay - Lung Cancer
Liquid Biopsy Metabolic Panel Assay - Lung Cancer Product Overview
Liquid Biopsy Metabolic Panel Assay - Lung Cancer Clinical Trial
Metabolomics-based Diagnostic Assay - Breast Cancer
Metabolomics-based Diagnostic Assay - Breast Cancer Product Overview
Metabolomics-based Diagnostic Assay - Cervical Cancer
Metabolomics-based Diagnostic Assay - Cervical Cancer Product Overview
Metabolomics-based Diagnostic Assay - Colorectal Cancer
Metabolomics-based Diagnostic Assay - Colorectal Cancer Product Overview
Metabolomics-based Diagnostic Assay - Gastrointestinal Cancer
Metabolomics-based Diagnostic Assay - Gastrointestinal Cancer Product Overview
Metabolomics-Based Diagnostic Assay - Melanoma
Metabolomics-Based Diagnostic Assay - Melanoma Product Overview
Metabolomics-based Diagnostic Assay - Prostate Cancer
Metabolomics-based Diagnostic Assay - Prostate Cancer Product Overview
POC Device - Monoclonal Antibodies
POC Device - Monoclonal Antibodies Product Overview
SSAT-Amantadine Assay - ELISA KIT
SSAT-Amantadine Assay - ELISA KIT Product Overview
SSAT-Amantadine Assay - Raman SERS
SSAT-Amantadine Assay - Raman SERS Product Overview
SSAT1 - Acetylamantadine Assay
SSAT1 - Acetylamantadine Assay Product Overview
BioMark Diagnostics Inc - Key Competitors
BioMark Diagnostics Inc - Key Employees
BioMark Diagnostics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
BioMark Diagnostics Inc, Recent Developments
Apr 14, 2026: BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
Jan 15, 2026: BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
Dec 31, 2025: BioMark: 2025 Achievements & 2026 Vision
Dec 23, 2025: BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
Dec 01, 2025: BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Nov 12, 2025: BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
Oct 07, 2025: BioMark's Liquid Biopsy Platform Selected for German Lung Cancer Screening Trial
Oct 07, 2025: BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
Sep 29, 2025: BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy
Sep 29, 2025: BioMark Secures Key Patents in Asia’s Largest Markets for Early Lung Cancer Liquid Biopsy
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
BioMark Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
BioMark Diagnostics Inc Pipeline Products by Equipment Type
BioMark Diagnostics Inc Pipeline Products by Indication
BioMark Diagnostics Inc Ongoing Clinical Trials by Trial Status
BioMark Diagnostics Inc, Key Facts
BioMark Diagnostics Inc, Major Products and Services
BioMark Diagnostics Inc Number of Pipeline Products by Development Stage
BioMark Diagnostics Inc Pipeline Products Summary by Development Stage
BioMark Diagnostics Inc Ongoing Clinical Trials by Trial Status
BioMark Diagnostics Inc Ongoing Clinical Trials Summary
Biomarker Assay - Ovarian Cancer - Product Status
Biomarker Assay - Ovarian Cancer - Product Description
Detection Test - COVID-19 - Product Status
Detection Test - COVID-19 - Product Description
Liquid Biopsy Metabolic Panel Assay - Breast Cancer - Product Status
Liquid Biopsy Metabolic Panel Assay - Breast Cancer - Product Description
Liquid Biopsy Metabolic Panel Assay - Glioblastoma - Product Status
Liquid Biopsy Metabolic Panel Assay - Glioblastoma - Product Description
Liquid Biopsy Metabolic Panel Assay - Head And Neck Cancer - Product Status
Liquid Biopsy Metabolic Panel Assay - Head And Neck Cancer - Product Description
Liquid Biopsy Metabolic Panel Assay - Lung Cancer - Product Status
Liquid Biopsy Metabolic Panel Assay - Lung Cancer - Product Description
Liquid Biopsy Metabolic Panel Assay - Lung Cancer - A Clinical Study Evaluating the Performance and Clinical Utility of BioMark's Liquid Biopsy Platform in the Tunisian Healthcare System
Liquid Biopsy Metabolic Panel Assay - Lung Cancer - Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen
Liquid Biopsy Metabolic Panel Assay - Lung Cancer - HANSE - Holistic Implementation Study Assessing a Northern German Interdisciplinary Lung Cancer Screening Effort, Population-based Screening Study -Prospective, Randomized Comparator Controlled
Metabolomics-based Diagnostic Assay - Breast Cancer - Product Status
Metabolomics-based Diagnostic Assay - Breast Cancer - Product Description
Metabolomics-based Diagnostic Assay - Cervical Cancer - Product Status
Metabolomics-based Diagnostic Assay - Cervical Cancer - Product Description
Metabolomics-based Diagnostic Assay - Colorectal Cancer - Product Status
Metabolomics-based Diagnostic Assay - Colorectal Cancer - Product Description
Metabolomics-based Diagnostic Assay - Gastrointestinal Cancer - Product Status
Metabolomics-based Diagnostic Assay - Gastrointestinal Cancer - Product Description
Metabolomics-Based Diagnostic Assay - Melanoma - Product Status
Metabolomics-Based Diagnostic Assay - Melanoma - Product Description
Metabolomics-based Diagnostic Assay - Prostate Cancer - Product Status
Metabolomics-based Diagnostic Assay - Prostate Cancer - Product Description
POC Device - Monoclonal Antibodies - Product Status
POC Device - Monoclonal Antibodies - Product Description
SSAT-Amantadine Assay - ELISA KIT - Product Status
SSAT-Amantadine Assay - ELISA KIT - Product Description
SSAT-Amantadine Assay - Raman SERS - Product Status
SSAT-Amantadine Assay - Raman SERS - Product Description
SSAT1 - Acetylamantadine Assay - Product Status
SSAT1 - Acetylamantadine Assay - Product Description
BioMark Diagnostics Inc, Key Employees
BioMark Diagnostics Inc, Other Locations
Glossary
List of Figures
BioMark Diagnostics Inc Pipeline Products by Equipment Type
BioMark Diagnostics Inc Pipeline Products by Development Stage
BioMark Diagnostics Inc Ongoing Clinical Trials by Trial Status

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us